Depending on the individual’s age, physical condition, and whether they have the del(17p) or TP53 mutation, different first line treatments may be offered. As of 2021, BTK inhibitors such as ibrutinib and acalabrutinib are often recommended for first line treatment of CLL. The medications fludarabine, cyclophosphamide, and rituximab were previously the initial treatment in those who are otherwise healthy.CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. In 2021, the estimated incidence of CLL in the United States is 21, 250 new cases and 4,320 deaths. The disease most commonly occurs in people over the age of 65 due to the accumulation of genetic mutations that occurs over time. Men are diagnosed around twice as often as women (6.8 to 3.5 ratio). It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer. Signs and symptoms
Most people are diagnosed as having CLL based on the result of a routine blood test that shows a high white blood cell count, specifically a large increase in the number of circulating lymphocytes. These people generally have no symptoms. Less commonly, CLL may present with enlarged lymph nodes. If enlarged lymph nodes are caused by infiltrating CLL-type cells, a diagnosis of small lymphocytic lymphoma (SLL) is made. Less commonly the disease comes to light only after the cancerous cells overwhelm the bone marrow resulting in low red blood cells, neutrophils, or platelets.
See also
Monoclonal B-cell lymphocytosis
Virtual karyotype
B-cell CLL/lymphoma

References
External links
Chronic Lymphocytic Leukemia Archived 2008-12-21 at the Wayback Machine at American Cancer Society
General information about CLL Archived 2004-10-19 at the Wayback Machine from the US National Cancer Institute
Cancer.Net: Chronic Lymphocytic Leukemia